Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit

Wyeth is now a wholly owned subsidiary of Pfizer1,500 enrolled

Overview

To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)

Study Type

OBSERVATIONAL

Enrollment

1,500

Conditions

Gram-Positive Bacterial Infections

Interventions

Piperacillin/tazobactam and other β-lactam/β-lactamaseDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients admitted to or transferred to the SICU. * Eligible patients will be patients of either sex, 18 years of age or older who are admitted or transferred to the SICU. * Provide written informed consent Exclusion Criteria: * Patients who have hypersensitivity to penicillin, cephalosporins or beta-lactamase inhibitors. * Females who are pregnant and breast feeding * Any underlying conditions or non-infectious diseases that will be ultimately fatal within 48 hours. * Those who have already been participating other clinical study related with antibiotics.

Locations (2)

Unnamed facility

Incheon, South Korea

Unnamed facility

Ulsan, South Korea

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.